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Distinct genetic alterations and luminal molecular subtype in nested variant of urothelial
carcinoma
Aims: Nested variant of urothelial carcinoma
(NVUC) is rare, and only a few small series exist.
Molecular characteristics and the classifying marker
profile as well as therapeutic targets of this specific
variant are mostly unknown. The aim of this study
was to characterise NVUC at the molecular level in
one of the largest cohorts to date. In addition, we
applied an immunohistochemical marker panel in
order to define the molecular subtype.
Methods and results: Sixty NVUC cases were collected
from different departments. TERT promoter mutation
analysis was carried out in all samples using SNaP-
shot analysis. Targeted sequencing of 48 cancer-re-
lated genes by next-generation sequencing (NGS)
analysis was performed in a subset of 26 cases.
Immunohistochemical markers CD44, CK5, CK14,
EGFR, p63, FOXA1, GATA3, CD24 and CK20 were
used to elucidate the molecular subtype. A total of
62.5% of NVUC cases harboured a mutation of the
TERT promoter. Additionally, TP53, JAK3 and
CTNNB1 were among the most frequently mutated
genes identified by NGS analysis. Subtyping revealed
that all NVUC express luminal markers such as
CD24, FOXA1, GATA3 and CK20.
Conclusions: In summary, NVUC belong to the lumi-
nal molecular subtype. Moreover, a subset of NVUC
seems to be characterised by mutations of the Wnt
and inflammatory pathways, including JAK3 muta-
tions, indicating a different biological background
compared to conventional urothelial bladder cancer.
Keywords: molecular subtype, nested variant, target sequencing, urothelial bladder cancer
Introduction
Divergent differentiation resulting in distinct histo-
morphological features is characteristic of urothelial
bladder cancer (UBC). In addition to frequent
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squamous and glandular differentiation, several rare
variants of urothelial differentiation are described in
the 2016 World Health Organisation (WHO) classifi-
cation, the nested variant (NVUC) being one of the
most common1,2 Since the first description of NVUC
by Talbert and Young in 1989, case reports as well
as very few studies with more than 30 cases have
mostly been reported.2–5 Histologically, small- to med-
ium-sized, sometimes confluent nests with occasional
central lumina and small tubules surrounded by a
frequently myxoid stroma are characteristic. Minimal
atypia and low to absent mitotic activity, especially in
the superficial parts, result in the often-cited ‘decep-
tively bland’ appearance of NVUC, which may be
hard to differentiate from benign mimics, such as
hyperplasia of Von Brunn’s nests and cystitis cystica/
glandularis. Diagnosis may be ensured by detection of
pleomorphic cells in the deeper parts of the tumour
and/or obvious invasive growth, especially in
tumours infiltrating the detrusor muscle.1,6 Moreover,
TERT promoter mutation analysis has been reported
as a helpful tool to discriminate between benign and
malignant lesions with nested morphology.7
Despite its bland morphology, clinical behaviour
and cancer-specific survival rates of NVUC are similar
to high-grade conventional UBC.4,6,8,9 Therefore,
aggressive treatment including multimodal therapy
with platinum-based chemotherapy is recom-
mended.5,10 Notably, there are no studies addressing
molecular therapeutic targets of NVUC, and data on
immunohistochemical characteristics are limited to
classical markers such as p53.4,5,8
In this study we aimed at further characterisation
of NVUC using targeted gene analysis of selected can-
cer-associated genes with a commercially available
sequencing panel and by SNaPshot analysis. Addi-
tionally, a immunohistochemical marker panel was
applied to classify the molecular subtype according to
current molecular taxonomy proposals in the litera-
ture.11–13
Materials and methods
S T U D Y C O H O R T
We collected archival formalin-fixed paraffin-embed-
ded tissue (FFPE) from transurethral resections and
cystectomies of 60 NVUC from our institutional files
and cooperating departments. NVUC cases included
tumours with a classical NVUC component or a clas-
sical NVUC component combined with < 10% large
nested variant urothelial carcinoma (LNUC). Pure
LNUC were excluded from the study. Tumours with
microcystic morphology were also included if com-
bined with a major classical NVUC component. Diag-
nosis was confirmed on haematoxylin and eosin-
stained slides by two experienced urological patholo-
gists (A.H., S.B.) and included semiquantitative
assessment of the percentage of variant morphologies.
Tumour grading was performed according to current
recommendations using both the 1973 and 2016
WHO classifications, which require documentation of
the worst grade in any of the tumour components,
regardless of the low nuclear grade of classical NVUC
areas.1 Institutional Review Board approval (Univer-
sity Hospital Erlangen) was obtained for molecular
analysis on archival material. Clinicopathological
characteristics of NVUC cases are shown in Table 1
and representative images are shown in Figure 1. As
the cases in our cohort were collected from several
institutions, no information regarding other clinical
variables is available.
D N A I S O L A T I O N
Tumour tissue from the NVUC component was man-
ually microdissected from previously marked areas to
achieve >80% NVUC purity. DNA isolation was per-
formed using the DNA preparation kit (Maxwell 16
System; Promega, Mannheim, Germany), according
to the manufacturer’s instructions. Only cases with a
sufficient amount of tumour and high-quality DNA
were further processed.
T E R T S E Q U E N C I N G
Mutation analysis of the TERT promoter was per-
formed as described recently.14 In brief, SNaPshot
analysis of the TERT core promoter was carried out
using an ABI Prism 3500 Genetic Analyzer and the
Snapshot-Multiplex-Kit (Applied Biosystems, Foster
City, CA, USA), according to the manufacturer’s
instructions. SNaPshot assays were used that
addressed hotspot mutations at positions 146,
124 and 57 base pairs (bp) of the TERT promoter.
All primers and reaction conditions are described else-
where in detail.14
N E X T - G E N E R A T I O N S E Q U E N C I N G
Library preparation for the commercially available
TruSeq Amplicon Cancer Panel (Illumina, San Diego,
CA, USA) representing 48 frequently relevant cancer
related genes (Table S1) was carried out according to
the manufacturer’s recommendations. A total of 60
libraries were sequenced in four separate runs
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[Illumina; Miseq System, mean coverage 91529
(43859; range = 1652–23 7889)]. Only non-syn-
onymous variants with an allele frequency >10% and
coverage >2009 were reported. One exception to this
rule was accepted in one case with CTNNB1 muta-
tion (allele frequency = 8.5%) due to confirmed
nuclear b-catenin expression by immunohistochem-
istry supporting the observed mutation.
J A K 3 S E Q U E N C I N G
Validation of the p.V722I of JAK3 was performed via
pyrosequencing. A 53 bp region was amplified using
the multiplex polymerase chain reaction (PCR)-kit,
according to the manufacturer’s instructions (Qiagen,
Hilden, Germany) and the following primers: forward:
50-cggtctgggaagtgtttagtg-30 and reverse: 50ag-
gatccagggcactgatg-30 (antisense conjugated to biotin).
The cycling conditions were as follows: a single cycle
of denaturation at 94°C for 5 min, 45 cycles at 94°C
for 1 min, 65°C for 1 min and 72°C for 1 min and a
final 10-min extension at 72°C. For pyrosequencing
(PyroMark Q24; Qiagen) single-stranded DNA was
prepared from biotinylated PCR product with strepta-
vidin-coated sepharose and the sequencing primer
using the PSQ Vacuum Prep Tool (Qiagen). The sam-
ples were then measured with the PyroMarkTM Q24
and analysed with the appropriate software (both
from Qiagen).
I M M U N O H I S T O C H E M I C A L A N A L Y S I S
A tissue microarray (TMA) of the cohort was con-
structed; one tissue core was punched per each NVUC
component and a marker panel was chosen to further
classify the tumours following current molecular tax-
onomy proposals: CK5, CK14, CD44, p63 and EGFR
were previously identified and used as so-called ‘basal
markers’.15 CK5, FOXA1 and GATA3 were predicted
to discriminate between luminal and basal subgroups
by a consensus conference and other studies. CK20
and CD24 are predominately represented among lumi-
nal tumours.15,16 Apart from a few exceptions (see
below), immunohistochemistry (IHC) was performed
on a BenchMark ULTRA Automated IHC/ISH Slide
Staining System (Ventana; Ventana Medical Systems,
Inc., Tucson, AZ, USA) on TMA slides (Table 2). Man-
ual staining was performed for FOXA1 (polyclonal,
1:1000; Abcam, Cambridge, UK, ab23738). CD24
IHC was performed automatically (dilution 1:5; SWA-
11; Ventana Medical Systems, Inc.) by our coopera-
tion partners at the Institute of Pathology, University
Hospital Bonn, Germany. IHC was considered positive
for b-catenin in the case of any nuclear staining. IHC
positivity for p53 was defined in tumours with strong
nuclear overexpression in at least 10% of tumour cells
Table 1. Study characteristics of the nested cohort
NVUC, n (%)
Sequenced
cases
All analysed
cases
Total number of cases 26 60
Gender
Male 19 (86.4) 43 (76.8)
Female 3 (13.6) 13 (23.2)
Not available 4 4
Stage
pT1 2 (7.7) 15 (25.0)
≥pT2 24 (92.3) 45 (75.0)
Grading WHO 1973*
G2 4 (15.4) 13 (21.2)
G3 22 (84.6) 47 (78.8)
Grading WHO 2016*
High-grade 26 (100.0) 60 (100.0)
Nodal status
pN0 8 (30.8) 13 (21.2)
pN+ 4 (15.4) 10 (16.7)
pNx 14 (53.8) 37 (62.1)
Lymphatic invasion
L0 13 (50.0) 35 (58.3)
L1 9 (34.6) 22 (36.7)
Lx 4 (15.4) 3 (5.0)
Variant purity
Pure 8 (30.8) 24 (40.0)
Mixed
Proportion of NVUC ≤ 50% 15 (57.7) 16 (26.7)
Proportion of NVUC > 50% 3 (11.5) 20 (33.3)
NVUC, Nested variant of urothelial carcinoma; WHO, World
Health Organisation.
*Tumour grading was performed according to the WHO classifica-
tions 1973 and 2016, documenting the worst grade in any of the
tumour components, regardless of the low nuclear grade of classi-
cal NVUC areas.
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or complete loss of p53 expression (‘null pheno-
type’).17 All other immunohistochemical markers
were analysed according to the immunoreactive score
(IRS) by Remmele and Stegner resulting from multipli-
cation of the percentage score (0 = 0, 1 = <10%,
2 = 10–50%, 3 = 51–80%, 4 = >80%) and intensity
score (assessment of the staining intensity of positive
cells: 0 = negative, 1 = weak, 2 = intermediate,
3 = strong).18
S T A T I S T I C A L A N A L Y S I S
The heatmap.2 function of the gplots package within
the R version 3.2.3 statistical environment was used
for non-hierarchical clustering based on immunoreac-
tive scores of the evaluated markers.
Results
H I S T O P A T H O L O G Y
Pure NVUC was found in 24 of 60 cases. NVUC
cases with mixed morphologies (36 of 60 cases)
showed most frequently additional conventional UBC
or micropapillary urothelial carcinoma, but also in
one case sarcomatoid, plasmacytoid, clear cell, squa-
mous and glandular UC morphological features,
respectively. Eighteen of 26 nested cases used for
NGS analysis were combined either with conven-
tional UBC (11 of 26), minor (~5%) LNUC (two of
A B
C D
E F
Figure 1. A–F, Nested variant
urothelial carcinoma: typical
histomorphology showing
small nests with occasional
central lumina and bland
cytology (H&E, magnifica-
tion: x100 and x200).
Table 2. Antibodies used for immunohistochemistry
Antibody Company Clone Dilution
Catenin, beta BD 14/beta-catenin 1:50
p53 Dako DO-7 1:50
CD44 Dako DF1485 1:40
CK20 Dako Ks20.8 1:50
CK5 Zytomed XM26 1:50
CK14 Ventana SP53 Ready-to-use
EGFR Novocastra EGFR25 1:50
GATA3 DCS L50-823 Ready-to-use
p63 DCS SFI-6 1:100
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26), micropapillary (three of 26), minor plasmacy-
toid (one of 26) or exophytic papillary (three of 26)
components.
T A R G E T E D M U T A T I O N A L A N A L Y S I S
TERT promoter mutations were identified in 62.5% of
all NVUC cases and were the most frequently
observed mutations (Table 3). Of 26 tumours that
were analysed by NGS, 11 cases were not mutated in
any of the interrogated cancer-related genes. Among
the mutations observed, TP53 and JAK3 were each
altered in five of 26 (19%), CTNNB1 in three of 26
(11.5%) and PIK3CA in two of 26 (7.7%) cases.
Mutation of FGFR2, FGFR3, PTEN, APC and KRAS
were each detected in one of 26 (3.8%) cases. No dif-
ferences between mixed and pure cases were detected
regarding the distribution of genetic alterations. All
mutations analysed by NGS are listed in detail in
Table 4.
TP53 alterations were among the most frequent
events in NVUC. Four of five TP53 altered cases dis-
played p53 overexpression (Figure 2A). The remain-
ing case showed a TP53 frameshift mutation and
weak nuclear immunoreactivity (~5%). JAK3 muta-
tions (n = 5) were as frequent as TP53 alterations, all
affecting the p.Val722Ile sites. Using pyrosequencing
analysis on the whole cohort, all JAK3 mutations
detected by NGS were confirmed. However, among
the remaining 34 cases no further JAK3-mutated case
could be observed (Table 3). Moreover, no differences
between the various mutated tumours concerning the
clinicopathological characteristics were observed
(data not shown).
Wnt pathway-associated genes were mutated in
four of 26 (15.4%) cases (one APC, three CTNNB1 –
mutually exclusive). All CTNNB1 mutations were typ-
ical hotspot mutations resulting in nuclear b-catenin
accumulation by immunostaining (Figure 2B). One
case harboured an inactivating APC mutation with
truncation protein, which also led to nuclear b-cate-
nin accumulation.
M O L E C U L A R S U B T Y P E I D E N T I F I E D B Y
I M M U N O H I S T O C H E M I C A L M A R K E R S
Differential expression of basal and luminal markers
by immunohistochemistry is shown in Table 5. Lumi-
nal markers CD24, FOXA1, GATA3 and CK20 were
mostly expressed at a high level with frequencies up
to 92.7%, whereas most cases were negative for basal
markers CD44, CK5, CK14 and EGFR (high expres-
sion frequencies between 26.4% and 38.9%). P63
was expressed in almost all cases, regardless of the
distribution of other markers. No differences between
mixed and pure cases were observed.
Figure 3 illustrates the expression levels, and non-
hierarchical clustering determined the similarity of
the used luminal and basal markers. In some cases,
with additional expression of basal markers, histo-
morphological re-evaluation showed frequent tubular
differentiation with staining of the basal cell layer
only.
Discussion
Despite the reported aggressive behaviour of NVUC,
their management is mainly based on radical cystec-
tomy and peri-operative chemotherapy.5,10,19 How-
ever, response to neoadjuvant chemotherapy seems
to be less efficient in tumours with variant histology,
and detection of potentially targetable molecular
alterations may be helpful.20 Therefore, we performed
NGS-based molecular analysis of one of the largest
cohorts, up to the present time, of NVUC, in order to
find pathogenic alterations and potential therapeutic
targets of this rare histological variant. In addition,
we used immunohistochemical markers in order to
define the molecular subtype.
Molecular changes were not significantly differ-
ent between tumours with pure nested and mixed
morphology. TERT promoter mutations have been
reported in approximately 79% conventional UBC
and have been discussed as an early event in
urothelial carcinogenesis.21 Zhong et al. found
TERT promoter mutation in 17 of 20 NVUC, but
none of its benign mimickers were analysed, thus
Table 3. TERT and JAK3 mutational analysis
NVUC cohort, n (%)
Total number of cases 60
TERT mutational status
Wild-type 18 (37.5)
Mutated 30 (62.5)
Not available 12
JAK3 mutational status
Wild-type 44 (89.8)
Mutated 5 (10.2)
Not available 11
NVUC, Nested variant of urothelial carcinoma.
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presenting a useful tool for distinguishing benign
and malignant lesions.7 In our cohort, we identi-
fied 62.5% TERT promoter mutated tumours point-
ing to the fact that irrespective of the
histomorphological variant, TERT promoter muta-
tion may occur early during tumour development
and supporting cancer diagnosis, especially in non-
muscle-invasive lesions.
Moreover, we found a (relatively) high frequency of
TP53 mutations (19.2%) in our NVUC cohort. Com-
pared to our results, the recent analysis of 412 MIBC
tumours in the TCGA cohort reported TP53 muta-
tions in 48%.12 Dysregulation of TP53 is known to
be important for the development of aggressive types
of bladder tumours such as MIBC, and also appar-
ently in a subset of NVUC.22
Table 4. Targeted sequencing of 26 NVUC
Patient Gene Allele frequency (%) Mutation Protein variant Location Function
1 JAK3, FGFR2 63.9/34.8 c.2164G>A/c.764G>A p.Val722Ile/p.Arg255Gln Exonic Missense
2 PIK3CA, CTNNB1 19.9/32.8 c.3012G>A/c.134C>T p.Met1004Ile/p.Ser45Phe Exonic Missense
3 CTNNB1 8.5 c.98C>T p.Ser33Phe Exonic Missense
4 No mutation identitfied
5 No mutation identitfied
6 No mutation identitfied
7 No mutation identitfied
8 JAK3 38.1 c.2164G>A p.Val722Ile Exonic Missense
9 No mutation identitfied
10 JAK3 55.3 c.2164G>A p.Val722Ile Exonic Missense
11 No mutation identitfied
12 PTEN 17.9 c.928G>A p.Asp310Asn Exonic Missense
13 No mutation identitfied
14 TP53 42.1 c.529_546del18 p.Pro177_Cys182del Exonic Deletion
15 TP53 25.0 c.380C>T p.Ser127Phe Exonic Missense
16 No mutation identified
17 TP53, CTNNB1 28.5/22.4 c.818G>A/c.133T>C p.Arg273His/p.Ser45Pro Exonic Missense
18 JAK3 54.3/49.2 c.2164G>A p.Val722Ile Exonic Missense
19 PIK3CA 17.8 c.1633G>A p.Glu545Lys Exonic Missense
20 TP53 18.0 c.404G>T p.Cys135Phe Exonic Missense
21 No mutation identified
22 FGFR3 21.1 c.746C>G p.Ser249Cys Exonic Missense
23 No mutation identified
24 KRAS 31.2 c.35G>T p.Gly12Val Exonic Missense
25 No mutation identified
26 TP53, JAK3, APC, FGFR2 21.8/56.6/
22.0/19.2
c.490_491insGT/
c.2164G>A/c.2673_2685
del13/c.778G>A
p.Lys164SerfsTer7/
p.Val722Ile/p.Glu892
ProfsTer20/p.Ala260Thr
Exonic Insertion,
deletion,
missense
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Next-generation sequencing analysis and pyrose-
quencing revealed JAK3 mutations in five of 52 anal-
ysed cases. All JAK3 mutations in our cohort were
located on p.Val722Ile and were validated by pyrose-
quencing. JAK3 is a tyrosine protein kinase, usually
expressed on haematopoietic cells (neutrophils, natu-
ral killer (NK) and T cells).23 The p.Val722Ile muta-
tion has been associated with a pseudo kinase
domain formation resulting in activation of the JAK3/
STAT3 pathway. This nucleotide polymorphism
(rs3213409) has been described with a minor allele
frequency of 0.0036 in the global population.24 JAK3
deregulation by activating mutations confers an inva-
sive growth advantage in extranodal nasal-type NK
cell lymphoma.25 Compared to conventional UBC,
only three (1.3%) JAK3-mutated cases, albeit located
on sites other than p.Val722Ile, were included in the
TCGA cohort.12 However, none of the three TCGA
cases showed typical nested-variant morphology
when re-analysing the representative uploaded official
images.26 There is an ongoing clinical trial with a
JAK3 inhibitor (CP690550), and among lung cancer
patients with JAK3 activation a long-term benefit of
programmed death ligand 1 (PD-L1) blockade has
been described, both indicating a potential therapeu-
tic option in this subset of NVUC.27
The Wnt-signalling pathway plays an important
role in several cancers, especially colorectal cancer.28
In UBC, its functional role is controversially discussed.
APC-promoter hypermethylation and proteins con-
nected to the Wnt/b-catenin pathway have been
associated with UBC progression.29,30 Accordingly, an
association of APC alterations or b-catenin accumula-
tion with higher frequencies of lymph node metastasis
and shorter disease-free and disease-specific survival
has been described in MIBC after surgery and adju-
vant chemotherapy.31 In UBC there are considerable
differences regarding the reported frequencies (0–
16%) for genetic alterations [mostly missense muta-
tions, frameshift deletions and loss of heterozygosity
(LOH)] of APC and CTNNB1, both responsible for b-
catenin deregulation and mutually exclusive.28,31,32
Five per cent of CTNNB1 as well as eight per cent of
APC altered tumours were detected in the TCGA
cohort.12 In our study, compared to conventional
UBC, NGS analysis revealed CTNNB1 and APC muta-
tions at a relatively high frequency of four of 26
(15%) tested cases, all confirmed by nuclear b-catenin
accumulation determined by immunohistochemistry.
In summary, our findings support a potential role of
the Wnt pathway in the development of a subset of
NVUC, and a link between specific pathway alter-
ations and histomorphological changes may exist.
Few alterations of receptor tyrosine kinases (RTKs)
were identified in NVUC. Specifically, compared to
conventional UBC (reported frequencies in the TCGA
cohort = 22%) we found PIK3CA mutations in 7.7%
NVUC.12 The PIK3CA oncogene encodes the catalytic
subunit of phosphatidylinositol 3-kinase involved in
cell growth and differentiation.33,34 PIK3CA muta-
tions may indicate response to PI3K-, mTOR- and
Akt-inhibitors.33 Mutations in other downstream sig-
nalling proteins of the PI3K and MAPK pathways
were only observed in two tested NVUC presenting
with a KRAS or PTEN mutation.34
FGFR3 mutations can be observed in the majority of
non-muscle invasive bladder cancers (NMIBC), but also
in approximately 20% of muscle-invasive bladder can-
cers (frequency within the TCGA cohort 14%).12 We
found the most common activating FGFR3
p.Ser249Cys mutation in a single NVUC case of our
cohort.12 To summarise, compared to conventional
UBC, especially NMIBC, FGFR3 mutations do not seem
to play a major role in this specific histological variant.
NVUCA B
n (%)
Total number of cases 26
4
0
4 (19.0)
17 (81.0)
5
4 (15.4)
22 (84.6)
TP53 expression
Aberrant pattern
Overexpression
Loss
Wild-type pattern
Not available
Positive
Negative
NVUC: Nested variant of urothelial carcinoma
β-Catenin expression
Figure 2. A, Results of immunohistochemical staining of TP53 and b-catenin of 26 analysed nested variant of urothelial carcinoma (NVUC)
cases. B, One representative case of nested variant urothelial carcinoma harbouring a CTNNB1 mutation resulting in nuclear b-catenin
accumulation by immunostaining (b-catenin, magnification: x400).
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In recent years, large-scale transcriptomic profiling
studies revealed differential clusters of urothelial car-
cinomas, providing a relatively good correlation with
the clinical behaviour of UBC.15 Moreover, consensus
meetings tried to translate the results gained from
mRNA clustering into distinct groups, which can be
roughly assigned to one of the two main subgroups
of basal and luminal tumours by application of
immunohistochemistry. Most reports propose CK5/
CK14 as basal markers, whereas FOXA1 and GATA3
are considered luminal markers.16,35 In our study,
most NVUC showed an expression of luminal mark-
ers, whereas basal markers were rarely expressed.
These findings are in line with three publications
which categorised variant tumours (including three
and seven NVUC) as luminal tumours.35–37 In con-
trast, there is also one study classifying nested
tumours to the basal subgroup; however, in this
study the case number was also low (n = 14) and
immunohistochemistry was restricted to basal mark-
ers only, and therefore may not provide a compre-
hensive picture of this specific variant.38 Among the
basal markers we applied p63, which is routinely
used as a basal marker in different organs (e.g. paro-
tid gland, prostate and breast). P63 was expressed in
most NVUC cases, limited to the basal lining of
Table 5. Immunohistochemical markers for molecular sub-
typing in nested variant of urothelial carcinoma
NVUC cohort, n (%)
Total number of cases 60
Basal markers
CD44
Negative 22 (40.7)
Weak 14 (25.9)
Strong 18 (33.3)
Not available 6
CK5
Negative 18 (33.3)
Weak 15 (27.8)
Strong 21 (38.9)
Not available 6
p63
Negative 3 (5.7)
Weak 10 (18.9)
Strong 40 (75.5)
Not available 7
EGFR
Negative 22 (41.5)
Weak 17 (32.1)
Strong 14 (26.4)
Not available 7
CK14
Negative 12 (22.6)
Weak 21 (39.6)
Strong 20 (37.7)
Not available 7
Luminal markers
CK20
Negative 15 (27.8)
Weak 20 (37.0)
Strong 19 (35.2)
Not available 6
Table 5. (Continued)
NVUC cohort, n (%)
GATA3
Negative 2 (3.6)
Weak 7 (12.7)
Strong 46 (83.6)
Not available 5
FOXA1
Negative 1 (1.8)
Weak 3 (5.5)
Strong 51 (92.7)
Not available 5
CD24
Negative 12 (22.2)
Weak 14 (25.9)
Strong 28 (51.9)
Not available 6
NVUC, Nested variant of urothelial carcinoma.
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tubular tumour structures, reminiscent of the basal/
luminal staining pattern frequently found in (benign)
salivary gland tumours. Due to these characteristics,
we did not include p63 in the heatmap analysis.
Moreover, p63 is commonly expressed in the majority
of urothelial tumours, regardless of the grade of differ-
entiation or molecular subtype, hence it is not
deemed appropriate for molecular subtyping in
urothelial carcinomas.39 Of course, the utilised lim-
ited marker panel has its restrictions: Kamoun et al.
presented in their draft the 2018 consensus molecu-
lar classification with six different luminal subtypes
based on RNA expression data.40 However, with the
IHC markers chosen for this study, and as translation
and simplification in terms of a consensus IHC panel
is still pending, we were not able to subcategorise the
luminal subtype of our cohort according to the men-
tioned RNA expression-based proposal.
Other limitations of our study are the restricted
number of explored target genes by NGS analysis as
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Figure 3. A, Heatmap presenting immunohistochemistry results for luminal and basal markers. Each column represents one tissue microar-
ray (TMA) spot; white fields represent non-available TMA spots; red fields represent high immunoreactive score (IRS) scores; green fields rep-
resent low IRS scores. B, Representative images of the different used immunohistochemical markers (Magnification: x200).
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well as the low number of sequenced NVUC. Further-
more, as most cases investigated were consultation
cases, unfortunately no follow-up were data avail-
able.
In summary, this study investigated the largest
cohort, to our knowledge, of NVUC to date and aimed
to the identify the mutational and molecular back-
grounds of this rare UC variant. NVUC seems to be
characterised by a high frequency of TERT mutations
and low frequency of mutations in FGFR3 and the
mTOR, MAPK and PIK3 pathways. Mutations of Wnt
and inflammatory pathways, including JAK3 muta-
tions, may indicate a differential mutational land-
scape of this specific histomorphological variant
compared to conventional UBC. Moreover, we were
able to assign NVUC to the luminal subtype of UC.
Our findings may be of significance in understanding
the pathogenesis of this rare variant and may guide
further diagnostic, prognostic and therapeutic appli-
cations.
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